The CagriSema weight-loss trials look at a different outcome. REIMAGINE 3 enrolled 274 adults with type 2 diabetes who were already taking basal insulin, with or without metformin. The main outcome was the change in HbA1c over 40 weeks [1].
Mean HbA1c started at 8.8%. The two CagriSema groups saw estimated declines of 2.33 and 2.10 percentage points, compared with 0.66 in the pooled placebo groups. Novo Nordisk funded the trial [1].
The trial recorded no severe hypoglycemia. Gastrointestinal symptoms made up most of the adverse events and were generally mild or moderate [1]. The guide to GLP-1 drugs and low blood sugar explains why insulin use matters when assessing that risk.
Novo Nordisk still described CagriSema as investigational in November 2026. The company submitted it to the FDA in December 2025 for weight management [2]. That filing covers a separate indication from the type 2 diabetes use studied here.